Bhimraj A,Morgan RL,Hirsch SA .2024 .Infectious Diseases Society of America guidelines on treating and managing patients with COVID-19. Clin Infect Dis: ciae435., : .
Chen Z,Yuan Y,Hu Q .2024 .SARS-CoV-2 immunity in animal models. Cell Mol Immunol, 21 : 119-133.
Corbett KS,Flynn B,Foulds KE .2020 .Evaluation of the mRNA1273 vaccine against SARS-CoV-2 in non-human primates. NEJM, 383(16) : 1544-1555.
Fan C,Wu Y,Rui X .2022 .Animal models for COVID-19: advances, gaps and perspectives. Sig Transd Targ Ther, 7(1) : 220.
Fumagalli V,Ravà M,Marotta D .2022 .Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Sci Immunol, 7 : eabl9929.
Giannakopoulos S,Strange DP,Jiyarom B .2023 .In vitro evidence against productive SARS-CoV-2 infection of human testicular cells: Bystander effects of infection mediate testicular injury. PLoS Pathog, 19(5) : e1011409.
Gorbalenya AE,Baker SC,Baric RS .2020 .The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 5(4) : 536-544.
Guebre-Xabier M,Patel N,Tian JH .2020 .NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine, 38(50) : 7892-7896.
Guo Y,Dong Y,Zheng R .2024 .Correlation between viral infections in male semen and infertility: A literature review. Virol J, 21 : 167.
Hoffmann M,Kleine-Weber H,Schroeder S .2020 .SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181(2) : 271-280.
Javadzadeh M,Moghadam FR,Erfanifar E .2024 .Evaluation of female infertility and viral diseases: A systematic review of coronaviruses. Sex Disabil, 42(4) : 567-589.
Jiang RD,Liu MQ,Chen Y .2020 .Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell, 182(1) : 50-58.
Kruglov AA,Bondareva MA,Gogoleva VS .2024 .Inactivated whole virion vaccine protects K18-hACE2 Tg mice against the Omicron SARS-CoV-2 variant via cross-reactive T cells and nonneutralizing antibody responses. Eur J Immunol, 54(3) : e2350664.
Kozlovskaya LI,Piniaeva AN,Ignatyev GM .2021 .Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Micro Infec, 10(1) : 1790-1806.
Lelis F,Byk LA,Pustylnikov S .2023 .Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models. Sci Rep, 13 : 21172.
Li Z,Xiang T,Liang B .2021 .Characterization of SARS-CoV-2- Specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting. Front Immunol, 12 : 802858.
Liu J,Budylowski P,Samson R .2022 .Preclinical evaluation of a SARSCoV-2 mRNA vaccine PTX-COVID19-B. Sci Adv, 8(3) : eabj9815.
Lu J,Tan S,Gu H .2024 .Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies. Emerg Micro Infec, 13(1) : 2321994.
MacDonald NE .2015 .Vaccine hesitancy: Definition, scope and determinants. Vaccine, 33(34) : 4161-4164.
Muñoz-Fontela C,Dowling WE,Funnell SGP .2020 .. Animal models for COVID-19. Nature, 586(7830) : 509-515.
Munshi I,Khandvilkar A,Chavan SM .2021 .An overview of preclinical animal models for SARS-CoV-2 pathogenicity. Indian J Med Res, 153(1) : 17-25.
Oladunni FS,Park JG,Pino PA .2020 .Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun, 11(1) : 6122.
Onen EA,Sonmez K,Yildirim F .2022 .Development, analysis, and preclinical evaluation of inactivated vaccine candidate for prevention of COVID-19 disease. All Life, 15(1) : 771-793.
Patone M,Handunnetthi L,Saatci D .2021 .Neurological complications after first dose of COVID-19 vaccines and SARSCoV-2 infection. Nat Med, 27(12) : 2144-2153.
Patone M,Thomas K,Hatch R .2021 .Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: An observational cohort study. Lancet Infect Dis, 21(11) : 1518-1528.
Sun SH,Chen Q,Gu HJ .2020 .A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe, 28(1) : 124-133.
Suthar M,Manning KE,Ellis ML .2025 .-adapted COVID19 vaccine improves neutralising activity against the XEC variant. Lancet Infect Dis, 25(3) : e122-e123.
Tanriover MD,Doğanay HL,Akova M .2021 .Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 398(10296) : 213-222.
Ulbegi PH .2023 .Comparison of mouse species in an in vivo SARS-CoV2 challenge model. Kafkas Univ Vet Fak Derg, 29(6) : 689-695.
Vogel AB,Kanevsky I,Che Y .2021 .BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 592(7853) : 283-289.
Winkler ES,Bailey AL,Kafai NM .2020 .SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol, 21(11) : 1327-1335.
Wu Z,Hu Y,Xu M .2021 .Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 21(6) : 803-812.
Yinda CK,Port JR,Bushmaker T .2021 .-hACE2 mice develop respiratory disease resembling severe COVID-19. PLoS Pathog, 17(1) : e1009195.
Yu J,Tostanoski LH,Peter L .2020 .DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 369(6505) : 806-811.
Zhang Y,Zeng G,Pan H .2020 .Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. Lancet Infect Dis, 21(2) : 181-192.